Abstract
This study evaluated the activity of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against nine epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemase in Naples, Italy. The isolates were susceptible to colistin but differed in their resistance to imipenem and rifampicin. Time-kill studies showed a bactericidal effect for colistin but not for imipenem, rifampicin or sulbactam/ampicillin used as single agents. Synergism was observed with combinations of rifampicin+imipenem or sulbactam/ampicillin for all isolates and with colistin+rifampicin for isolates showing higher minimum inhibitory concentrations for rifampicin. Combined use of the antimicrobials tested may provide good therapeutic options for OXA-58 carbapenemase-producing A. baumannii infections.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acinetobacter Infections / epidemiology*
-
Acinetobacter Infections / microbiology
-
Acinetobacter baumannii / drug effects*
-
Acinetobacter baumannii / enzymology
-
Acinetobacter baumannii / genetics
-
Acinetobacter baumannii / isolation & purification
-
Ampicillin / pharmacology
-
Anti-Bacterial Agents / pharmacology*
-
Bacterial Proteins / biosynthesis*
-
Carbapenems / pharmacology
-
Colistin / pharmacology
-
Disease Outbreaks*
-
Drug Resistance, Multiple, Bacterial*
-
Drug Synergism
-
Electrophoresis, Gel, Pulsed-Field
-
Humans
-
Imipenem / pharmacology
-
Italy / epidemiology
-
Microbial Sensitivity Tests
-
Rifampin / pharmacology
-
Sulbactam
-
beta-Lactamases / biosynthesis*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Carbapenems
-
Imipenem
-
Ampicillin
-
beta-Lactamases
-
carbapenemase
-
Sulbactam
-
Rifampin
-
Colistin